

#innovacion  
#ayudascdti  
#asesoramiento  
#internacionalizacion



# Horizonte Europa

# Misión Cáncer: Conv. 2024

Marta Gómez Quintanilla

[marta.gomez@cdti.es](mailto:marta.gomez@cdti.es)

[@EU\\_RDI\\_LifeSci](https://www.linkedin.com/in/martagq)

**Evento-Taller: ecosistema y oportunidades  
de financiación europea para Cáncer**  
24 de mayo de 2024



Enlaces web en las imágenes y cuadros de texto  
Consulten las fuentes oficiales

# Misión Cáncer



**Mejorar la vida de más de 3 millones de personas para 2030, mediante la prevención, la curación y para que los afectados por el cáncer, incluidas sus familias, vivan más y mejor, junto con el Plan Europeo de Lucha contra el Cáncer.**

Luchar contra el cáncer  
desde todos **los frentes**



**1** > **comprender**  
el cáncer y sus  
factores de riesgo;

**2** > **evitar** lo que sea evitable;

**3** > optimizar **el**  
**diagnóstico y el**  
**tratamiento;**

**4** > mejorar la **calidad de vida** de las  
personas durante y después de la  
enfermedad, al tiempo que se garantiza  
un acceso equitativo para todo el mundo.

**Prioridades transversales:** Acceso equitativo para todos,  
medicina personalizada, innovación, cáncer pediátrico

# Convocatorias Misión Cáncer

## Programa de Trabajo 2021-2022 – 254,7 M€

- **HORIZON-MISS-2021-UNCAN-01:** 3M€ - 1 CSA
- **HORIZON-MISS-2021-CANCER-02:** 125,65 M - 3 RIAs
- **HORIZON-MISS-2022-CANCER-01:** 126 M€ - 2 RIAs + 3 CSAs

## Programa de Trabajo 2023-2024 – 229,7 M€

- **HORIZON-MISS-2023-CANCER-01:** 110,7 M€ - 3 RIAs + 1 IA
- **HORIZON-MISS-2024-CANCER-01:** 119 M€

# Resultados preliminares España

# Convocatorias abiertas HORIZON-MISS-2024-CANCER-01

| Title                                                                                                                                        | Tipo | Presupuesto | Contribución UE/proy (M€) | # Proy que se espera financiar | Apertura  | Cierre    |
|----------------------------------------------------------------------------------------------------------------------------------------------|------|-------------|---------------------------|--------------------------------|-----------|-----------|
| HORIZON-MISS-2024-CANCER-01-01: Use cases for the UNCAN.eu research data platform                                                            | RIA  | 30          | ≈30                       | 1                              | 18-abr-24 | 18-sep-24 |
| HORIZON-MISS-2024-CANCER-01-02: Support dialogue towards the development of national cancer data nodes                                       | CSA  | 3           | ≈3                        | 1                              | 18-abr-24 | 18-sep-24 |
| HORIZON-MISS-2024-CANCER-01-03: Accessible and affordable tests to advance early detection of heritable cancers in European regions          | IA   | 35          | 10-12                     | 3                              | 18-abr-24 | 18-sep-24 |
| HORIZON-MISS-2024-CANCER-01-04: Support a pragmatic clinical trial programme by cancer charities                                             | CSA  | 3           | ≈3                        | 1                              | 18-abr-24 | 18-sep-24 |
| HORIZON-MISS-2024-CANCER-01-05: Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer | RIA  | 36          | 4-6                       | 6                              | 18-abr-24 | 18-sep-24 |
| HORIZON-MISS-2024-CANCER-01-06: An information portal for the European Cancer Patient Digital Centre                                         | IA   | 12          | ≈12                       | 1                              | 18-abr-24 | 18-sep-24 |

## HORIZON-MISS-2024-CANCER-01-01: Use cases for the UNCAN.eu research data platform

Submission: **18.09.2024**; **R&I action**; EUR 30 M/proposal; **70 pages**; networking & project cluster

### Scope:

- **Develop the UNCAN.eu platform** by integrating and, where relevant, complementing existing (or planned) data nodes of European research infrastructures and/or other national infrastructures linking cancer data holders (e.g. hospitals, research centres, comprehensive cancer centres, etc.).
- Provide open-source **tools, services and workflows to researchers** across data nodes for access and efficiently use cancer datasets for research. Capitalise on EOSC4cancer's achievements, integrating and expanding as appropriate the available tools and solutions.
- Design and implement a **rich and diverse portfolio of use-cases** to inform, steer the development and demonstrate the validity of the UNCAN.eu platform. Use cases should focus on ambitious research questions that are in line with the Cancer Mission objectives.
- At the same time, use-cases should be functional to the design and implementation of UNCAN.eu to **increase the diversity of digital tools and services available for cancer researchers**. The mobilisation and integration of a large amount of different data and a balanced participation of clinicians, disease experts and data scientists will be essential to achieve the objectives. Emphasis to FAIR data (findable, accessible, interoperable, reuse) should be given.



(cont.)

- Develop innovative approaches, to integrate and analyse **heterogeneous data from multiple sources and different research domains**. In this regard, at least one use-case should integrate imaging, digital pathology and genomic data, using and/or contributing with new data sources to the Genomics Data Infrastructure (GDI) and Cancer Image Europe (EUCAIM) .
- During the project lifetime, new data sources that might become available at a later stage can be accommodated as well as **allowing additional data holders to join** the UNCAN.eu platform.
- Establish **appropriate links with relevant EU-funded initiatives** (e.g. EHDS and others) and with the successful proposal resulting from the topic HORIZON-MISS-2024-CANCER-01-02

#### Expected outcome:

- The UNCAN.eu platform is developed by federating a network of cancer data nodes built on European and national computing infrastructures that link different cancer data holders across European countries.
- Use-cases focusing on the understanding of cancer initiation and progression are designed and implemented by multidisciplinary teams to develop tools and services for working with FAIR data.
- Researchers and clinicians use the electronic resources provided by the UNCAN.eu platform to access, manage and analyse data of heterogeneous types and belonging to different research domains at an unprecedented scale.



## HORIZON-MISS-2023-CANCER-01-02: Support dialogue towards the development of national cancer data nodes

Submission: 18.09.2024; CSA; EUR 3 M/proposal; networking & project cluster

### Scope:

- **Foster the development of national cancer data nodes through policy dialogues** at national level with relevant actors in the research and innovation community, digital health and public health policy.
- Identify and **build synergies between European infrastructures** related to health data access and health data sharing for primary and secondary data uses (e.g. MyData@eu, HealthData@eu, ELIXIR, BBMRI, and others)
- Identify **challenges and barriers** to the effective future implementation of the UNCAN.eu and the ECPDC platforms at national and European levels and propose operational solutions to overcome them.
- Identify **population subgroups with poor digital skills** and geographical areas with limited digital resources that might prevent the use of those platforms and propose solutions to reduce the digital divide.

### Expected outcome:

- Advance the process of establishing National cancer data nodes
- Way forward to overcome potential barriers that may prevent the effective implementation of UNCAN.eu and ECPDC digital platforms

38

## HORIZON-MISS-2024-CANCER-01-03: Accessible and affordable tests to advance early detection of heritable cancers in European regions

Submission: **18.09.2024**; EUR 10-12 M/proposal; **Innovation action (TRL 5-7)**; **written commitment from regions**; evaluation portfolio approach; synergies; networking & project cluster

### Scope:

- Validate easy-to-use, affordable and accessible genetic, multi-omics or other biomarker-based cancer tests for early detection of cancers with an underlying **heritable genetic risk** for **uptake in regional or national healthcare systems**. Validation may include for example clinical studies, socio-economic or technological feasibility studies.
- Stratify the to-be-tested population by sex, gender, age or other determinants.
- Be compliant with GDPR and take into account socio-economic status, limited health literacy, limited awareness of disease symptoms and access for people in remote and rural areas.
- Tests can be based on, **for example**, polygenic cancer risk scores, algorithms, machine learning, biomarkers, cell lines, organoids, liquid biopsies, medical devices, or wearables and other digital applications.
- Co-create with **end-users** - including citizens and health professionals, such as psychologists, living in the targeted regions - aspects such as the innovation life cycle, priority definition, design, development, testing and piloting stages as well as risk assessment, counselling, health education, and acceptability.
- Extensively pilot and upscale genetic, multi-omics or other biomarker-based testing or use in early detection programmes in at least three regions across at least three different Member States or Associated Countries. One of the three targeted regions should be within the following Member States: **Bulgaria, Croatia, Cyprus, Czech Republic, Estonia, Greece, Hungary, Latvia, Lithuania, Malta, Poland, Portugal, Romania, Slovakia or Slovenia**.
- Preferably work together with one of the **EIT-Health KIC networks** to establish appropriate contacts, and support relevant entrepreneurship, education, training, capacity building or innovation aspects for interested stakeholders in the targeted regions.



## HORIZON-MISS-2024-CANCER-01-03: Accessible and affordable tests to advance early detection of heritable cancers in European regions (2)

### Expected outcome:

- People and their families at **heritable genetic risk** of developing cancer, will benefit from the outcomes of evidence-based, tailored, affordable and accessible early detection, based on accessible and affordable tests;
- Civil society, foundations, and innovators will seize opportunities to respectively co-create, support or commercialise early detection programmes based on genetic, multi-omics or other biomarker-based tests.
- **Regional and national policymakers and authorities** in Member States and Associated Countries will engage in piloting, scaling up or implementing suitable early detection and treatment of people and their families with underlying heritable genetic risk in European regions based on genetic, multi-omics or other biomarker-based accessible and affordable tests, including legislative policies.

## HORIZON-MISS-2024-CANCER-01-04: Support a pragmatic clinical trial programme by cancer charities

Submission: 18.09.2024; EUR 3 M/proposal; CSA; networking & project cluster

### Scope:

- Together, registered cancer charities and foundations across Europe, organise, fund and implement at **least two transnational calls** for proposals, resulting in grants to **academic investigator-led** third parties to conduct randomised multi-centre **pragmatic clinical trials**.
- Organise **annual networking** activities between charities, the successful academic investigators, **citizen representatives** and stakeholders across Member States and Associated Countries across Europe.
- The chosen intervention(s) should be adapted to the particular needs of the target population and to the specificities of the provision of care at local, regional, or national level, duly reflecting the diversity across Member States and Associated Countries.
- The chosen intervention(s) should take into account socio-economic and biological **stratification**. All data should be disaggregated by sex, gender, age and other relevant variables, such as by measures of socio-economic status.
- The successful grants to third parties will address interventions for patients with cancers with a **5-year overall survival of less than 50% from time of diagnosis or rare cancers**, at any stage of the disease, for any cancer subtype, in any age group or part of society.

### Expected outcome:

- Together, a network of registered cancer charities and foundations support multi-centre, transnational pragmatic clinical trials on cancers with a 5-year overall survival less than 50% from time of diagnosis or rare cancers using their own resources.
- Cancer patients and their caregivers have access to more effective and patient-centred, treatment and care solutions.
- Researchers, innovators, and professionals from different disciplines and sectors ensure accessibility and re-usability of relevant trial data, to support the UNCAN.eu research data platform, **which is currently in preparation**.
- National healthcare providers, policymakers and authorities in European regions, Member States and Associated Countries have the evidence to implement affordable and accessible treatment and care solutions in their healthcare systems.

41



## HORIZON-MISS-2024-CANCER-01-05: Improving the understanding and management of late-effects in adolescents and young adults (AYA) with cancer

Submission: 18.09.2024; EUR 4-6 M/proposal; **R&I action**; networking & project cluster

- **Scope:** AYA cancer patients (age range 15-39) too often experience late-effects due to treatment (e.g. chronic pain and fatigue, cardiovascular disease, organ and skin alterations, fertility problems, mental health issues etc). Proposals should focus on one or more cancer types and address one of the following interventions:
  - Building on data from existing or newly established AYA patient cohorts, obtain a thorough assessment by cancer type of the **prevalence, specific effect(s), severity, time of onset, relative risk, and risk factors associated to late effects** in AYA cancer patients.
  - Develop, test and scale-up evidence-based **screening methods for early detection of late-effects** in AYA cancer patients;
  - Develop, test and scale up in real-life settings, **innovative, holistic approaches and tools (including digital tools), optimising cancer treatment and follow-up regimens** to prevent, reduce and/or effectively manage late-effects, including psycho-social aspects.
- **Expected outcome:** Proposals under this topic should aim to deliver results that are directed and tailored towards and contribute to the following expected outcomes:
  - **Increased awareness and understanding** of the incidence, severity, and impact of late effects in AYA cancer survivors;
  - Development of **effective interventions to support AYA patients and survivors** in preventing, reducing and managing late-effects;
  - **Improved quality of life** and long-term outcomes for AYA cancer survivors.

42



## HORIZON-MISS-2024-CANCER-01-06: An information portal for the European Cancer Patient Digital Centre

Submission: 18.09.2024; Innovation action; EUR 12 M/proposal

### Scope:

- **Design, develop and deploy, a pilot ECPDC information portal** to complement the existing Knowledge Centre on Cancer (KCC).
- The knowledge base of the information portal will cover the cancer patient journey from diagnosis to life after cancer. It will **provide evidence-based information** on diagnosis, treatment options, rehabilitation, management of recurrence and palliative care.
- The selection of the information provided to the users should be based on **explicit and robust criteria and be transparent**.
- Provide a **validated workflow** for updating the knowledge base when new clinical information and scientific evidence arise. The development and implementation of human centric AI-based tools for this task is envisaged.
- Improve ECPDC portal user experience by implementing an **AI-based virtual assistant** to deliver information tailored to user cultural background, individual (clinical) circumstances, needs, preferences and/or expectations. This virtual assistant should be designed and tested in real-world patient populations for acceptability and value provided.

(cont.)

- All the developed **IT-solutions and workflows should be open source** and made available. The involvement of AI-researchers, clinicians, epidemiologists, guideline developers, service design specialists and patient organisation representatives are envisaged.
- The pilot ECPDC information portal should also **include other information** for cancer patients, survivors and their families (e.g. options to cross-border health care, participation to clinical research, psychosocial and legal support options, guidance and support for returning to study or to work, financial issues and survivors' rights etc.)
- **Test and validate the pilot ECPDC information portal** by an appropriate number of cancer patients and survivors of different cancer types and age groups.

#### **Expected outcome:**

- The ECPDC information portal is an entry point to quality information for cancer patients, survivors, their families and care givers, covering the cancer patient journey from diagnosis to treatment and post treatment care and life after cancer.
- The ECPDC information portal complements the Knowledge Centre on Cancer (KCC) by integrating additional trusted information on cancers beyond what is currently available in the KCC.
- The ECPDC information portal implements human-centric AI-based solutions to manage and systematically update the information provided to the users and to facilitate the user experience.

# Ref. European Cancer Patient Digital Centre (ECPDC)




Figure 1: Cited description of the scope of the ECPDC and picture from EU Cancer Mission Implementation Plan, pg. 22<sup>1</sup>



Funded by  
the European Union

RTD-2022-MVP-0012

Study providing an operational concept for a  
European Cancer Patient Digital Centre

Offered by

**IBIH** Berlin Institute  
of Health  
@Charité

Center for Digital Health, Berlin Institute of  
Health (BIH)  
at Charité Universitätsmedizin Berlin  
Prof. Dr. Roland Ellis  
Kapelle-Ufer 2  
10117 Berlin

SHORT SUMMARY

2024-04-05

# Aspectos diferenciales en convocatorias (i)



**AMBICIÓN:** La convocatoria debe fijar **objetivos ambiciosos y relevantes**; unos objetivos menos ambiciosos reducirían el nivel de excelencia e innovación.

# Aspectos diferenciales en convocatorias (i)



**AMBICIÓN:** La convocatoria debe fijar **objetivos ambiciosos y relevantes**; unos objetivos menos ambiciosos reducirían el nivel de excelencia e innovación.

**ÁMBITO DE APLICACIÓN:** similar al “estándar” Horizonte Europa, importantes diferencias:

- Implicar sistemáticamente a los ciudadanos, incluidos los pacientes y sus cuidadores.
- Participación mayor de lo habitual de disciplinas y sectores diferentes.
- Mayor atención a la generación de resultados tangibles, prestando atención al impacto social, TRLs altos, a la implementación y a la investigación aplicada, a las soluciones orientadas a la atención sanitaria.
- Participación de las Regiones / Estados Miembros y los Países Asociados (si pertinente y dependiendo de dónde estén las competencias en cada caso).

# Aspectos diferenciales en convocatorias (i)




**AMBICIÓN:** La convocatoria debe fijar **objetivos ambiciosos y relevantes**; unos objetivos menos ambiciosos reducirían el nivel de excelencia e innovación.

**ÁMBITO DE APLICACIÓN:** similar al “estándar” Horizonte Europa, importantes diferencias:

- Implicar sistemáticamente a los ciudadanos, incluidos los pacientes y sus cuidadores.
- Participación mayor de lo habitual de disciplinas y sectores diferentes.
- Mayor atención a la generación de resultados tangibles, prestando atención al impacto social, TRLs altos, a la implementación y a la investigación aplicada, a las soluciones orientadas a la atención sanitaria.
- Participación de las Regiones / Estados Miembros y los Países Asociados (si pertinente y dependiendo de dónde estén las competencias en cada caso).

**COLABORACIÓN CON INICIATIVAS:** Se indica en el texto la petición de colaboración, si procede, con otras iniciativas relevantes (e.g. **Centro Común de Investigación - Knowledge Center on Cancer**) y se buscan sinergias a todos los niveles.

# KNOWLEDGE CENTRE ON CANCER



The **KCC** fosters **independent scientific alignment, coordination and support** to EC cancer-related policies and activities.

We act as:

- **evidence-clearing house for policy making** on cancer prevention, early detection, treatment and survivorship.
- manager of the **EU Cancer Information System**.
- developer of **European guidelines** and quality assurance schemes on cancer.
- **data hub for cancer and 'honest data broker'** via the European Health Data Space.

# Aspectos diferenciales en convocatorias (ii)

**CLÚSTERES:** Los proyectos financiados se agrupan según los ejes de la Misión: Prevention, including screening; Understanding; Diagnostics and Treatment & Quality of Life.

*In order to address the objectives of the Mission on Cancer, participants will collaborate in project clusters to leverage EU-funding, increase networking across sectors and disciplines, and establish a portfolio of Cancer Mission R&I and policy actions.*

Las propuestas deben prever fondos en sus presupuestos para estas actividades:

*The Commission will facilitate Mission-specific coordination through future actions, notably fostering exchanges with other proposals funded under this topic. Hence, successful applicants will be asked to join the 'xxx' cluster for the Mission on Cancer established in 202X. In this regard, the Commission will take on the role of facilitator, including with relevant initiatives and stakeholders, if appropriate.*


*Therefore, proposals should include a budget for networking, attendance at meetings, and potential joint activities without the prerequisite to give details of these at this stage. Examples of these activities are the organisation of joint workshops, the exchange of knowledge, the establishment of best practices, or the initiation of joint communication activities with projects funded under other clusters and pillars of Horizon Europe, or other EU programmes, as appropriate. The details of joint activities will be defined during the grant agreement preparation phase and during the life of the project.*

# CLÚSTERES de proyectos: Aumentan sinergias e IMPACTO

Los proyectos financiados son agrupados según ejes de la Misión:

- **Comprensión del cáncer**
- **Prevención**
- **Diagnóstico y Tratamiento**
- **Calidad de Vida**

**2021-2024**



Develop new methods and technologies for screening and early detection  
HORIZON-MISS-2021-CANCER-02-01

Improving and upscaling primary prevention of cancer through implementation research  
HORIZON-MISS-2022-CANCER-01-01

Enhance cancer prevention through behaviour change  
HORIZON-MISS-2023-CANCER-01-02

Early detection heritable cancers in European regions  
HORIZON-MISS-2024-CANCER-01-03

Pragmatic clinical trials to optimise treatment for cancer patients  
HORIZON-MISS-2022-CANCER-01-03

Strengthen research capacities of comprehensive cancer infrastructures  
HORIZON-MISS-2022-CANCER-01-02

Pragmatic clinical trials minimally invasive diagnostics  
HORIZON-MISS-2023-CANCER-01-03

Support a pragmatic clinical trial programme by cancer charities  
HORIZON-MISS-2024-CANCER-01-04

Develop and validate a set of quality-of-life measures for cancer patients and survivors  
HORIZON-MISS-2021-CANCER-02-02

Towards the creation of a European Cancer Patient Digital Centre  
HORIZON-MISS-2022-CANCER-01-04:

Improve quality of life for survivors of childhood cancer (Best practices and tools)  
HORIZON-MISS-2023-CANCER-01-04

Improving the understanding and management of late-effects in adolescents and young adults  
HORIZON-MISS-2024-CANCER-01-05

An information portal for the European Cancer Patient Digital Centre  
HORIZON-MISS-2024-CANCER-01-06

Preparing UNCAN.eu, a European initiative to understand cancer  
HORIZON-MISS-2021-UNCAN-01-01

Better understand healthy versus cancer cells at individual and population level  
HORIZON-MISS-2021-CANCER-02-03

Better understand tumour-host interactions in cancer patients  
HORIZON-MISS-2023-CANCER-01-01

Use cases for the UNCAN.eu research data platform  
HORIZON-MISS-2024-CANCER-01-01

Creation of national cancer mission hubs - HORIZON-MISS-2022-CANCER-01-05

National cancer data nodes - HORIZON-MISS-2024-CANCER-01-02

# Aspectos diferenciales en convocatorias (il)



**LÍMITE DE PÁGINAS:** CANCER-01-01. UNCAN *The page limit of the applications is 70 pages.*

# Aspectos diferenciales en convocatorias (iii)



**LÍMITE DE PÁGINAS:** CANCER-01-01. UNCAN *The page limit of the applications is 70 pages.*

**ELEGIBILIDAD:** CANCER-01-03. Heritable cancers. *A written commitment is required from the supportive administrative entity of the geographical area in which the action proposed will be implemented, expressed by a letter of intent annexed to the proposal and signed by that entity.*

# Aspectos diferenciales en convocatorias (iii)



**LÍMITE DE PÁGINAS:** CANCER-01-01. UNCAN *The page limit of the applications is 70 pages.*

**ELEGIBILIDAD:** CANCER-01-03. Heritable cancers. A written commitment is required from the supportive administrative entity of the geographical area in which the action proposed will be implemented, expressed by a letter of intent annexed to the proposal and signed by that entity.

**UMBRALES:** 12/15: 4/5 (Excelencia), 4/5 (Impacto) y 3/5 (Implementación).

# Aspectos diferenciales en convocatorias (iii)



**LÍMITE DE PÁGINAS:** CANCER-01-01. UNCAN *The page limit of the applications is 70 pages.*

**ELEGIBILIDAD:** CANCER-01-03. Heritable cancers. A written commitment is required from the supportive administrative entity of the geographical area in which the action proposed will be implemented, expressed by a letter of intent annexed to the proposal and signed by that entity.

**UMBRALES:** 12/15: 4/5 (Excelencia), 4/5 (Impacto) y 3/5 (Implementación).

## PORTFOLIO APPROACH:

CANCER-01-03 : *In order to ensure a balanced Cancer Mission project portfolio and to achieve the Mission's goal, grants will be awarded to applications not only in order of ranking but also to one application that fully addresses cancer in children, adolescents or young adults (meaning people between birth and the age of 24), provided that the application attains all thresholds.*

CANCER-01-05. AYA. • *at least one application that fully addresses understanding of late effects in AYA cancer; • at least one application that fully addresses development of screening methods for early detection of late effects in AYA cancer • at least one application that fully addresses management of late effects in AYA cancer; are funded provided that these applications attain all thresholds.*

# Aspectos diferenciales en convocatorias (iii)



**LÍMITE DE PÁGINAS:** CANCER-01-01. UNCAN *The page limit of the applications is 70 pages.*

**ELEGIBILIDAD:** CANCER-01-03. Heritable cancers. A written commitment is required from the supportive administrative entity of the geographical area in which the action proposed will be implemented, expressed by a letter of intent annexed to the proposal and signed by that entity.


**UMBRALES:** 12/15: 4/5 (Excelencia), 4/5 (Impacto) y 3/5 (Implementación).

## PORTFOLIO APPROACH:

CANCER-01-03 : *cancer in children, adolescents or young adults (meaning people between birth and the age of 24*

CANCER-01-05. AYA. *Subproyectos*

**TRLs:** CANCER-01-03 : Activities are expected to achieve TRL 5 to 7 by the end of the project



# Aspectos diferenciales en convocatorias (iv)



## PARTICIPACIÓN DE:

**CIUDADANOS** (incluidos pacientes y cuidadores): la sociedad civil, las organizaciones y comunidades de pacientes y cuidadores deben abordarse de forma coherente. Evitar centrarse en un número limitado de organizaciones de defensa de los pacientes.

**USUARIOS FINALES:** Ejemplos de modelos de investigación y servicios para el usuario final en varios Estados Miembro:

- Living Lab at IrsiCaixa AIDS Research Institute (ES): <https://www.scishops.eu/case-study-living-lab-for-health-spain/>
- Living lab services Kuopio University Hospital (FI): <https://www.psshpi.fi/web/en/organisation/living-lab>
- Living Labs at INCa (FR): <https://gnius.esante.gouv.fr/en/players/player-profiles/living-lab-institut-national-du-cancer>
- European Network of Living Labs (ENoLL): <https://enoll.org/>
- Los usuarios finales podrían incluir también centros oncológicos, autoridades y servicios sanitarios nacionales y regionales, comunidades locales (por ejemplo, escuelas, ciudades...).

# Más información & Brokerage event

## EU Missions info days

The event aims to inform potential applicants about the new topics included in the EU Missions work programme 2024

📅 25 April 2024 - 26 April 2024

🕒 09:30 (GMT+02:00)



## Cancer Mission

📅 26 April 2024  
🕒 09:30 - 11:30



EUROPEAN UNION

### Agenda



- 09:30 Welcome & Introduction - Barbara Kerstiens, Head of Unit Combatting Diseases, DG RTD and Silvia Hrubanova, Unit Cancer, Health in all policies, DG SANTE
- 09:40 Cancer Mission: Introduction & Background - Annika Nowak, DG RTD
- 09:48 Cancer Mission: Project Clusters - Kay Duggan-Walls, DG RTD
- 09:56 Overview of the European Health and Executive Agency - Ioannis Vouldis, HaDEA
- 10:01 EIT Health – CEO Jean-Marc Bourez
- 10:11 Short Q&A Session
- 10:21 Launch of Slido polls 1 & 2
- 10:25 Presentation of Work Programme 2024 - Jan van de Loo, Angelo Solimini, DG RTD
- 10:56 Q&A on Work Programme 2024 - Jan van de Loo, Angelo Solimini
- 11:30 Closing remarks - Barbara Kerstiens
- 11:35 End

Please identify your organisation when asking questions

## EU MISSIONS



## Horizon Europe Missions Brokerage Event

21-22 May 2024



Online




### Deadlines

### Task


|                   |                                          |
|-------------------|------------------------------------------|
| 17 May            | Deadline for registration                |
| 29 April - 22 May | Online scheduling of bilateral meetings  |
| 22 May            | B2B meeting schedules finalised at 19.00 |
| 21 May            | Plenary Session (10.00 - 12.00)          |
| 21 May            | B2B Meetings (13.00 - 19.00)             |
| 22 May            | B2B Meetings (10.00 - 19.00)             |

# Webs Misión Cáncer

## General



## Implementación






# Establecer colaboraciones:

Esencial estar preparado antes de la publicación de las convocatorias



# Identificar oportunidades:

Hay que conocer las distintas formas de ejecución de prioridades



# Buscar apoyo:

Oficinas propias apoyo / Puntos Nacionales de Contacto

# Apoyo en Salud HE: Equipo CDTI y NCPs



carolina.carrasco@cdti.es



marta.gomez@cdti.es



marta.dediego@cdti.es

## Puntos Nacionales de Contacto



Carolina Carrasco

CDTI

carolina.carrasco@cdti.es

+34 91 581 55 62



Marta de Diego

CDTI

marta.dediego@cdti.es

+34 91 581 55 62



Marta Marin

FECYT, MCIN

marta.marin@fecyt.es


+34 91 425 09 09

@HorizonteEuropa  
@CDTI\_innovacion


[www.horizonteeuropa.es](http://www.horizonteeuropa.es)  
[www.cdti.es](http://www.cdti.es)

# Portal oficial de Horizonte Europa (España)

www.horizonteeuropa.es



Listado de NCPs



# Lista distribución CDTI - Clúster 1 Salud

EL CDTI AYUDAS Y SERVICIOS ¿EMPRENDES? COMUNICACIÓN

PROGRAMA MARCO - HORIZONTE EUROPA

Horizonte Europa - general

- ☐ Programa Marco: Información general

Clúster 1 - Salud

- ☐ Programa Marco: Salud

Clúster 3 - Seguridad Civil para la Sociedad


- ☐ Programa Marco: Seguridad

Clúster 4 - Mundo Digital, Industria y Espacio

- ☐ Programa Marco: Digital
- ☐ Programa Marco: Industria
- ☐ Programa Marco: Espacio

Clúster 5 - Clima, Energía y Movilidad

- ☐ Programa Marco: Clima
- ☐ Programa Marco: Energía
- ☐ Programa Marco: Movilidad



[Externo] Noticias Clúster 1 Salud

CDTI - Horizonte Europa <cdti.web@cdti.es>  
Para: Marta Gómez Quintanilla

ATENCIÓN: Este correo electrónico se originó fuera de la organización.  
No haga clic en enlaces, ni abra archivos adjuntos, ni envíe información a menos que reconozca al remitente y sepa que el contenido es seguro.

**HORIZONTE EUROPA**

**Noticias Clúster 1 Salud**

Estimado/a amigo/a:

A continuación, informamos de las últimas novedades relacionadas con el Clúster de Salud de Horizonte Europa:

**Taller de preparación de propuestas del clúster salud 2024**

El 15 de marzo, la FECYT y CDTI en colaboración con el Hospital Universitario La Paz - IdiPaz, organizan un seminario de preparación de propuestas. La jornada constará de cuatro sesiones temáticas: ensayos clínicos, ética, lump sum y escritura de propuestas. Al finalizar la jornada, se realizará revisión de propuestas por las NCPs de Salud y de asuntos Legales y Financieros.

Más información y registro en el enlace: <https://www.horizonteeuropa.es/taller-de-preparacion-de-propuestas-del-cluster-salud-2024>

**Workshop "Unlocking Success: Insider Insights for Winning Horizon Europe Health Proposals"**

El 12 de marzo (14 h a 16:30 h) la red de NCPs de salud HNN3.0 organiza en formato online el workshop "Unlocking Success: Insider Insights for Winning Horizon Europe Health Proposals" con el objetivo de proporcionar consejos para la preparación de las secciones de excelencia, impacto e implementación de las propuestas.

Más información y registro en el enlace: <https://www.healthncp.net/news-events/hnn30-workshop-unlocking-success-insider-insights-winning-horizon-europe-health>

Grabación y presentaciones disponibles de la Jornada Informativa Nacional de IHI

# Construyendo **JUNTOS** el futuro





+ info sobre programas y ayudas  
para la  
internacionalización de la I+D+I española



@HorizonteEuropa - @CDTI\_innovacion